Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Anika Therapeutics (ANIK) Invested Capital: 2010-2025

Historic Invested Capital for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to $146.8 million.

  • Anika Therapeutics' Invested Capital fell 18.38% to $146.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.8 million, marking a year-over-year decrease of 18.38%. This contributed to the annual value of $154.0 million for FY2024, which is 27.45% down from last year.
  • As of Q3 2025, Anika Therapeutics' Invested Capital stood at $146.8 million, which was down 0.59% from $147.7 million recorded in Q2 2025.
  • Over the past 5 years, Anika Therapeutics' Invested Capital peaked at $303.7 million during Q2 2021, and registered a low of $146.8 million during Q3 2025.
  • Moreover, its 3-year median value for Invested Capital was $208.5 million (2024), whereas its average is $202.7 million.
  • Per our database at Business Quant, Anika Therapeutics' Invested Capital rose by 5.28% in 2021 and then tumbled by 33.50% in 2024.
  • Anika Therapeutics' Invested Capital (Quarterly) stood at $291.4 million in 2021, then decreased by 2.00% to $285.6 million in 2022, then decreased by 25.67% to $212.3 million in 2023, then declined by 27.45% to $154.0 million in 2024, then fell by 18.38% to $146.8 million in 2025.
  • Its Invested Capital stands at $146.8 million for Q3 2025, versus $147.7 million for Q2 2025 and $148.4 million for Q1 2025.